Jeff Fairman

Juvaris BioTherapeutics, Inc. develops novel, adjuvanted vaccines and immunotherapeutics to treat infectious disease and cancer. The company was founded by Martin D. Cleary, Jeff Fairman and Steven W. Dow in February 2003 and is headquartered in Burlingame, CA.

Clingenix, Inc. provided pharmacogenomics services and diagnostic products. The company was headquartered in Sunnyvale, CA.

Celera Diagnostics LLC discovers, develops and commercializes molecular diagnostics. The firm enables physicians to diagnose, monitor and treat disease. It manufactures products for infectious disease testing and for genetic conditions such as cystic fibrosis. The company was founded in 2001 by Kathy Ordoñez and is headquartered in Alameda, CA.

Valentis lead drug candidate, Deltavasc, may treat peripheral arterial and ischemic heart disease with a gene that spurs new blood vessels to form (a process known as angiogenesis). In early stages of development are DNA vaccines for HIV, hepatitis C, and other viral infections. Another drug candidate, eNOS, could prevent tissue rejection in transplant recipients. The company licenses its technology -- include the GeneSwitch platform, which can turn off or on gene therapies -- to other drugmakers. These licensees include Genzyme, Pfizer, and GlaxoSmithKline.

Applied Biosystems, Inc. is a company that provides integrated systems for sequencing, flow cytometry, and various types of PCR. The company is based in Foster City, CA. The company's products cover the entire process from sample preparation to data analysis. The company was founded by Chris Yoo, Marvin H. Caruthers, Michael W. Hunkapiller, and Leroy E. Hood. Applied Biosystems was acquired by Invitrogen Corp. from Applera Corp. on November 21, 2008 for $6,417.85 million.

Colby is transitioning to a clinical stage drug development company. The company was launched as a Wisconsin Alumni Research Foundation (WARF) spin-out and is strategically aligned with leading clinicians and drug discovery scientists at the University of Wisconsin Paul P. Carbone Comprehensive Cancer Center (UWCCC). Colby is accessing data from funded grants and private investment to develop its therapeutic drugs for therapy-resistant and hypoxic conditions. Colby's lead drugs have unique mechanisms of action and target specific pathways. The company is focused on clinical development of its lead drugs, CPC-100 and -200, in patients with recurrent PCa and other solid tumors, respectively. In 2010, Colby plans to launch a Phase I/IIa study of CPC-100 in men with PCa who fail Androgen Depletion Therapy, as evidenced by rising PSA levels. CPC-200 is being scheduled for a Phase I/IIa in men with high-risk tumors. Colby's two pipeline drugs, CPC-300 and CPC-410 for therapy-resistant metastatic and hypoxic tumors are in late pre-clinical development and are funded by federal grants, including an awarded Colby SBIR grant and by private investors. The Company has demonstrated safety of its lead drugs following efficacy studies in rodents and toxicology studies in mice, rats, and dogs.